LARGE B-CELL LYMPHOMA

This study tests a new treatment called ronde-cel for people with aggressive B-cell lymphoma that has come back or not responded to at least two prior therapies. The treatment uses a patient's own immune cells that are modified to target two markers (CD19 and CD20) on cancer cell…

This study tests a new treatment called ronde-cel, which uses a patient's own immune cells engineered to attack two targets on lymphoma cells. It is for people with large B-cell lymphoma that has come back or not responded to initial treatment. About 400 participants will receive…

This study tests a new treatment called cemacabtagene ansegedleucel (cema-cel) for adults with large B-cell lymphoma who have tiny amounts of cancer left after their first round of treatment. About 250 participants will either receive this CAR T cell therapy or be watched closely…

This early-phase study tests whether a drug called NT-I7 (a long-acting form of a natural immune protein) can safely boost the activity of CAR T-cells in people with relapsed or refractory large B-cell lymphoma. About 24 participants will receive NT-I7 after standard CAR T-cell t…

This study tests whether giving an extra antibody drug (mosunetuzumab or glofitamab) after CAR-T cell therapy can improve outcomes for people with relapsed or refractory large B-cell lymphoma. About 42 participants will receive the combination to see if it leads to complete remis…

This early-phase study tests whether a second infusion of the CAR T-cell therapy axicabtagene ciloleucel (Axi-Cel) is safe for adults with aggressive non-Hodgkin lymphoma who are at high risk of the cancer returning after their first standard CAR T treatment. About 20 participant…

This study tests a combination of three drugs (glofitamab, a PD-1 inhibitor, and lenalidomide) in 24 people with a type of large B-cell lymphoma that has returned or not responded to treatment and has a specific gene change (TP53). The goal is to see if this combination can shrin…

This study tests a new gene therapy called VNX-101 for people with certain blood cancers (like leukemia and lymphoma) that have returned or not responded to standard treatments. The therapy aims to help the body fight cancer cells by targeting a protein called CD19 found on these…

This study tests whether adding the drug epcoritamab to a standard chemotherapy mix (rituximab, cyclophosphamide, vincristine, prednisone) can better control newly diagnosed diffuse large B-cell lymphoma (DLBCL) in older or frail adults who cannot receive strong anthracycline che…

This study tests whether giving focused radiation to large tumors before CAR-T cell therapy can improve cancer control in people with aggressive large B-cell lymphoma. About 27 participants with tumors at least 5 cm will receive the combined treatment. The goal is to see if this …

This trial tests a new treatment called WZTL-002 for people with large B-cell lymphoma that came back or didn't get better after standard chemo. It uses the patient's own immune cells, modified to fight cancer, and is given as a one-time infusion. About 60 adults aged 18 to 75 wi…

This study looks back at the medical records of 250 adults with large B-cell lymphoma who received the drug Glofitamab through a special access program in France. The goal is to see how well the drug works and what side effects occur in everyday practice, especially in patients w…

This study tests whether the drug loncastuximab tesirine can help people with large B-cell lymphoma who only had a partial response after CAR T-cell therapy. About 30 adults will receive the drug to see if it can turn a partial response into a complete remission. The goal is bett…

This study aims to develop and test a communication training program called Hematolo-GIST for doctors who treat large B-cell lymphoma. The goal is to help doctors better discuss the diagnosis and plan future care with their patients. The study will enroll 48 participants, includi…

This study aims to find out what factors help predict whether CAR-T therapy will work for people with relapsed or refractory large B-cell lymphoma. Researchers will look at patient health records, tumor features, and immune system changes in 80 participants. The goal is to better…